Lateral flow technologies play a vital role in the rapid diagnosis of numerous infections and diseases. Up to 1000x brighter than Quantum dots, CPNs™ provide extraordinary sensitivity, in addition to stability over wide ranges of pH and temperature, making them an outstanding tool for use in lateral flow Rapid Diagnostic Tests (RDTs). When used in conjunction with a temperature stable targeting agent, an all environment RDT is feasible and this is currently under development. CPNs™’ high fluorescent intensity enables low levels of accurate target detection, enabling the potential of early disease diagnosis. CPNs™ can also be manipulated using magnets, with the potential to further increase the sensitivity of target detection in lateral flow assays, widening the detection window. When a magnet is applied to the test line, CPNs™ are locally concentrated, resulting in improved test sensitivity and accuracy.
The wide CPN™ colour range, which extensively spans both the visible and IR spectrum, facilitates an ultra-sensitive, multiplexed, mass screening capability. This enables several targets to feature on one test strip for rapid and multiple disease diagnosis in the same test.
Infrared Lateral Flow
CPN™ 900 (IR-I) and CPN™ 1130 (IR-II) are also capable of infrared lateral flow studies where they offer a number of advantages over gold nanoparticles. When imaged with an infrared camera, IR CPNs™ can facilitate the distinct detection of molecules present at vastly different concentrations and allow target quantification at pg/mL levels, with no background signal detected from the nitrocellulose strip.
CPNs™ Enhance Current Lateral Flow Tests
CPN™ RDTs are therefore capable of enhancing current lateral flow technology used in critical rapid diagnostic tests, aiding early interventions in a huge range of detectable infectious and other diseases, with earlier diagnosis helping to guide their management and treatment options.